Adagio Therapeutics has spied a path to FDA authorization for its tarnished COVID-19 antibody. Having been brought low in an omicron farrago, Adagio is now looking to positive phase 2/3 data against earlier variants to help secure ADG20 a spot among the arsenal of preventive and therapeutic antibodies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,